ALATROFLOXACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H25F3N6O5
Molecular Weight	558.5091
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]1[C@H]2CN(C[C@@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=C(F)C=C(F)C=C5)C(O)=O

InChI

InChIKey=UUZPPAMZDFLUHD-VUJLHGSVSA-N

InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H25F3N6O5
Molecular Weight	558.5091
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_Pharmacology
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/trovan.html

Alatrofloxacin is a fluoroquinolone antibiotic developed as a mesylate salt and was sold under brand name Trovan, but was withdrawn from the U.S. market in 2001. Trovan was indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin, which is responsible for therapeutic effect. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Plasmodium falciparum 75 Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12878530	Inhibitor 8504
Streptococcus pneumoniae 25 Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894	Inhibitor 8504
Moraxella catarrhalis 10 Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894	Inhibitor 8504
Staphylococcus aureus 70 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20407243	Inhibitor 8504
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Nosocomial pneumonia 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Pneumonia 91 Sources: https://www.drugs.com/pro/trovan.html	Curative	Approved 8583	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Intra-abdominal infections 50 Sources: https://www.drugs.com/dosage/trovan.html	Curative	Approved 8583	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Complicated skin and skin structure infections 11 Sources: https://www.drugs.com/dosage/trovan.html	Curative	Approved 8583	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Pneumonia 91 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Complicated intra-abdominal infections 20 Sources: https://www.drugs.com/pro/trovan.html#Indications_And_Usage	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Gynecologic infections 19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Skin infections 59 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997

C_max

Value	Dose	Analyte	Population
1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.7 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
4.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg 1 times / day multiple, intravenous dose: 300 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
9.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34.6 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
32.2 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
46.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
46.3 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg 1 times / day multiple, intravenous dose: 300 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
12.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	300 mg 1 times / day multiple, intravenous dose: 300 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
20.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
25.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
22% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
28.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Vomiting (1 patient) Lightheadedness (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	Disc. AE: Gastrointestinal disorder NOS, CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder NOS (11 patient) CNS disorder (NOS) (4 patients) Dizziness (2 patients) Dermatitis (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/

AEs

AE	Significance	Dose	Population
Vomiting	1 patient	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Lightheadedness	4 patients	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Nausea	4 patients	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years Health Status: healthy Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Gastrointestinal disorder NOS	11 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
Dermatitis	2 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
Dizziness	2 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
CNS disorder (NOS)	4 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741	UGT 219 sulfotransferases 39

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23401306/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_clinpharmr.pdf#page=4 Page: 4.0	yes
sulfotransferases 39	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_clinpharmr.pdf#page=4 Page: 4.0	yes

Sourcing

Vendor/Aggregator	ID	URL
AHH Chemical co.,ltd	MB-18104	http://www.ahhchemical.com/product/MB-18104.html
AK Scientific, Inc. (AKSCI)	X2115	http://www.aksci.com/item_detail.php?cat=X2115
Alfa Chemistry	146961-76-4	https://www.alfa-chemistry.com/alatrofloxacin-cas-146961-76-4-item-290329.htm
BioSynth	J-008289	https://www.biosynth.com/en/products/all-products/products/J-008289.html
BOC Sciences	146961-76-4	https://www.bocsci.com/l-alaninamide-l-alanyl-n-1a-5a-6a-3-6-carboxy-8-2-4-difluorophenyl-3-fluoro-5-8-dihydro-5-oxo-1-8-naphthyridin-2-yl-3-azabicyclo-3-1-0-hex-6-yl-cas-146961-76-4-item-166826.html
ChemMol	99045884	http://www.chemmol.com/chemmol/99045884.html
eNovation Chemicals	D674817	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674817
Lab Network	LN01284338	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01284338
MuseChem	M093915	https://www.musechem.com/product/M093915.html
Smolecule	S517830	http://www.smolecule.com/products/s517830
THE BioTek	bt-259048	https://www.thebiotek.com/product/inhibitors/bt-259048
ChEBI	CHEBI:9763	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9763
MolPort	MolPort-018-615-902	https://www.molport.com/shop/molecule-link/MolPort-018-615-902
ZINC	ZINC000100030989	http://zinc15.docking.org/substances/ZINC000100030989

PubMed

Title	Date	PubMed
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.	2002-03	11864947
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.	2002-02	11892894
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.	2002-02	11858908
Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.	2002-02	11850165
In vitro assessment of urinary isolates of ampicillin-resistant enterococci.	2002-02	11847942
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae.	2002-01	11821174
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine.	2002-01	11821166
Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.	2002-01	11791092
Bactericidal mechanism of gatifloxacin compared with other quinolones.	2002-01	11751786
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.	2002-01	11751769
Gatifloxacin: a review of its use in the management of bacterial infections.	2002	11790160
A critical review of the fluoroquinolones: focus on respiratory infections.	2002	11790155
Quinolones and false-positive urine screening for opiates by immunoassay technology.	2001-12-26	11754677
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].	2001-12	11856983
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].	2001-12	11856982
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.	2001-12	11837640
Peripheral neuropathy associated with fluoroquinolones.	2001-12	11793615
Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.	2001-12	11786656
Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.	2001-12	11786655
Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.	2001-12	11733478
pH-metric solubility. 3. Dissolution titration template method for solubility determination.	2001-12	11684402
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.	2001-11-01	11687317
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.	2001-11	11885973
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.	2001-11	11679567
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.	2001-11	11679549
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.	2001-10	11691572
Seizures associated with fluoroquinolones.	2001-10	11675843
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.	2001-10	11581436
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.	2001-10	11581236
Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.	2001-10	11581235
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.	2001-09-19	11561138
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.	2001-09-15	11517444
Drug company sued over research trial in Nigeria.	2001-09-08	11564494
Human research. Nigerian families sue Pfizer, testing the reach of U.S. law.	2001-09-07	11546842
Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.	2001-09	11673035
Is more than one quinolone needed in clinical practice?	2001-09	11573860
Future of the quinolones.	2001-09	11562902
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.	2001-09	11533001
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.	2001-08	11576789
Use of broad spectrum antibiotics in six non-university Swiss hospitals.	2001-07-28	11582634
Experimental intravitreal application of trovafloxacin in rabbits.	2001-07-21	11464076
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.	2001-07	11474633
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	2001-07	11463526
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].	2001-06	11704772
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.	2001-04	11493408
Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico.	2001	11760159
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.	2001	11713894
Latest industry information on the safety profile of levofloxacin in Japan.	2001	11549788
Comparison of side effects of levofloxacin versus other fluoroquinolones.	2001	11549784
History of quinolones and their side effects.	2001	11549783

Patents

Sample Use Guides

In Vivo Use Guide

Nosocomial Pneumonia - 300 mg I.V. followed by 200 mg oral, 10–14 days Community Acquired Pneumonia - 200 mg oral or 200 mg I.V. followed by 200 mg oral, 7–14 days Gynecologic and Pelvic Infections - 300 mg I.V. followed by 200 mg oral, 7–14 days

Route of Administration: Other

In Vitro Use Guide

Trovafloxacin inhibited Escherichia coli growth with MIC50 = 0.125mg/L

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:40:14 GMT 2025` Edited by `admin` on `Wed Apr 02 07:40:14 GMT 2025`
Record UNII	7QVV6I50DT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALATROFLOXACIN [VANDF]

Preferred Name

English

ALATROFLOXACIN

Official Name

English

Alatrofloxacin [WHO-DD]

Common Name

English

alatrofloxacin [INN]

Common Name

English

7-((1R,5S,6S)-6-((S)-2-((S)-2-AMINOPROPIONAMIDO)PROPIONAMIDO)-3-AZABICYCLO(3.1.0)HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C795